AXIM Biotechnologies, Inc. is an international healthcare solutions company. The Company is focused on diagnosis and treatment for oncology and SARS-CoV-2, or COVID-19. The Company's COVID-19 rapid neutralizing antibody test ImmunoPass is the rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering human host cells. In addition, the Company is developing rapid diagnostic tests for the early detection of cancer and small molecules drugs to treat cancer and block metastasis. The Company's lead product candidate, SPX-1009, which is an anti-metastatic treatment and to measure levels of Quiescin Sulfhydryl Oxidase 1 (QSOX1) related to cancer. The Company is also engaged in point-of-care (POC) lab testing systems designed to assist eye-care physicians in detecting and quantifying a variety of biomarkers associated with external ocular disorders.